Aurinia posted $70 million in revenue and $21.5 million in net income for Q2 2025, supported by solid LUPKYNIS sales. The company also improved operating cash flow and announced expanded share repurchase plans.

Aurinia Pharmaceuticals saw a robust quarter driven by LUPKYNIS sales, leading to a net income of $23.3M and positive operating cash flow.

Aurinia Pharmaceuticals reported strong financial results for Q4 2024, with a significant increase in total revenue and a return to net income profitability. The company's key product, LUPKYNIS, drove sales growth, and the company is progressing with its pipeline development.

Aurinia Pharmaceuticals reported strong Q3 2024 results with a 24% increase in total net revenue and a 36% increase in net product revenue compared to the same period last year. The company is undergoing a strategic restructuring to focus on LUPKYNIS growth and AUR200 development, expecting significant cost savings.

Aurinia Pharmaceuticals reported a strong second quarter with a 38% increase in total net revenue, reaching $57.2 million. The company also generated $15.8 million in free cash flow and narrowed its 2024 net product revenue guidance to $210 to $220 million. Additionally, Aurinia is advancing its AUR200 pipeline asset for autoimmune diseases and anticipates regulatory approval of LUPKYNIS in Japan in the second half of the year.

Aurinia Pharmaceuticals Inc. reported a strong fourth quarter and full-year 2023, with a focus on driving commercial execution of LUPKYNIS and implementing operational changes to enhance shareholder value. The company reaffirmed its 2024 net product revenue guidance and announced a share repurchase program of up to $150 million.

Aurinia Pharmaceuticals reported a net product revenue of $40.8 million for Q3 2023, a 60% increase year-over-year. Total net revenue was $54.5 million. The company narrowed its 2023 net product revenue guidance to $155 - $160 million. They received a $10 million milestone payment from Otsuka for securing pricing and reimbursement approvals in Europe.

Aurinia Pharmaceuticals reported a strong second quarter in 2023, with net revenue increasing to $41.5 million, a 47% increase compared to the prior year. The company is increasing its full-year revenue guidance to $150 - $160 million for net product sales of LUPKYNIS.

Aurinia Pharmaceuticals reported a strong first quarter in 2023, with net revenue reaching $34.4 million, a 59% increase compared to the same period last year. The company is increasing its full-year revenue guidance to $135 - $155 million.

Aurinia Pharmaceuticals Inc. reported a total net revenue of $28.4 million for the fourth quarter of 2022, representing a 21% increase compared to the same period in 2021. The company's cash, cash equivalents, and investments totaled $389.4 million as of December 31, 2022. The company reiterated its net product revenue guidance of $120 to $140 million for fiscal year 2023.

Aurinia Pharmaceuticals Inc. reported a total net revenue of $55.8 million for Q3 2022, which includes a $30.0 million milestone from Otsuka. The company is adjusting its net product revenue guidance to $100-105 million from sales of LUPKYNIS for 2022 and issuing preliminary net product revenue guidance for 2023 in the range of $120-140 million.

Aurinia Pharmaceuticals Inc. reported a net revenue increase to $28.2 million for Q2 2022 and maintained its net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022. The company had $391.7 million in cash and investments as of June 30, 2022.

Aurinia Pharmaceuticals reported net revenue of $21.6 million for Q1 2022, a significant increase compared to the prior year period. The company maintains its net revenue guidance of $115 million to $135 million for 2022.

Aurinia Pharmaceuticals Inc. reported Q4 2021 net revenue of $23.4 million, a 60% increase from the previous quarter, and full year 2021 net revenue of $45.6 million. The company had $466.1 million in cash, cash equivalents, and investments as of December 31, 2021. Aurinia projects net revenue guidance of $115-$135 million for 2022.

Aurinia Pharmaceuticals reported a net revenue of $14.7 million for the third quarter of 2021, a 122% increase from the second quarter of 2021. The company also added two preclinical assets to its pipeline and saw steady increases in LUPKYNIS patient start forms and conversion rates.

Aurinia Pharmaceuticals Inc. reported a net revenue of $6.6 million for the second quarter of 2021, a 624% increase from the first quarter of 2021. The company received 415 patient start forms (PSFs) for LUPKYNISTM during the quarter, representing a 60% increase from the first quarter. The company anticipates that annual net revenue for LUPKYNIS will be in the range of $40 to $50 million for 2021.

Aurinia Pharmaceuticals reported a net loss of $50.4 million for the quarter ended March 31, 2021. Revenues were $0.9 million, primarily from commercial sales of LUPKYNIS, which began in January 2021. Cash and cash equivalents and investments totaled $360.9 million as of March 31, 2021.